hotspot -WSS

hotspot

author：focus 2025-10-02 22:57:51 - browse：146

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： There's an unseen cost to disruptive road

WSS

FDA sets aggressive timeline for overhauling inspection procedures

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

What causes osteoarthritis? Researchers study link to brain protein

A pediatrician calls for Congress to pass the child tax credit deal

Weight bias in eating disorder treatment complicated by new weight loss drugs

Inaction leaves children at risk from dangerous chemotherapy drug

knowledge

hotspot

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Head of FDA's diagnostics center, who led through Covid, retires

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Death of patient in Alzheimer’s trial raises question of possible risks

After affirmative action ruling, medical educators look to 'holistic review'

Do masks work? RCTs can't tell us

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

State Dept. review finds Biden bears some blame for Afghanistan failures

HPV vaccine, cervical cancer study delivers historic results

Wikipedia

FDA sets aggressive timeline for overhauling inspection procedures

WATCH: Why do fingernails fall off when they're damaged?

Immunocompromised patients offer clues on chronic Covid

Mass General, Mayo Clinic look to monetize custom

High breast density mammograms need follow

Dana Farber says 6 studies to be retracted and 31 corrected

focus

hotspot

focus

knowledge